Oncol Rep:TGF-β通过MAPK促进乳腺癌侵袭转移

2012-07-02 Beyond 生物谷

乳腺癌的发展和转移与转化生长因子-β(TGF-β)细胞因子的异常相关。在乳腺癌早期发展阶段,TGF-β呈现肿瘤抑制活性,能抑制细胞的增殖,诱导肿瘤细胞死亡,而在乳腺癌晚期阶段,TGF-β促进肿瘤细胞的侵袭和转移。 一直以来TGF-β的潜在致癌作用分子机制尚不完全清楚,近日Daroqui MC 等研究人员在Oncol Rep杂志上发表论文证实了TGF-β信号在癌症发生发展中的具体作用,研究者使用L

乳腺癌的发展和转移与转化生长因子-β(TGF-β)细胞因子的异常相关。在乳腺癌早期发展阶段,TGF-β呈现肿瘤抑制活性,能抑制细胞的增殖,诱导肿瘤细胞死亡,而在乳腺癌晚期阶段,TGF-β促进肿瘤细胞的侵袭和转移。

一直以来TGF-β的潜在致癌作用分子机制尚不完全清楚,近日Daroqui MC 等研究人员在Oncol Rep杂志上发表论文证实了TGF-β信号在癌症发生发展中的具体作用,研究者使用LM3乳腺腺癌细胞株探讨了TGF-β的致癌活性。激酶失活的TGF-β受体表达能降低肿瘤细胞基础水平以及TGF-β诱导的肿瘤细胞的侵袭。

信号传导分析研究表明,p38MAPK和MEK在TGF-β刺激肿瘤细胞运动和侵袭过程中发挥重要作用。TGF-β破坏上皮细胞的肌动蛋白结构(肌动蛋白结构主要支持细胞间的粘连),并增加线性肌动蛋白丝。阻断RAF-MEK信号通路能增强TGF-β诱导的肌动蛋白表达上调,而p38MAPK的抑制剂却能逆转上述效应。

此外,TGF-β刺激基质金属蛋白酶MMP-9的分泌。该研究表明,TGF-β有助于乳腺癌细胞的侵袭行为。MEK-ERK和p38 MAPK通路是TGF-β致癌的关键所在,也是干预治疗乳腺癌的潜在靶标。

doi:10.3892/or.2012.1813
PMC:
PMID:

TGF-β autocrine pathway and MAPK signaling promote cell invasiveness and in vivo mammary adenocarcinoma tumor progression.

Daroqui MC, Vazquez P, Bal de Kier Joffé E, Bakin AV, Puricelli LI.

Breast cancer progression and metastasis have been linked to abnormal signaling by transforming growth factor-β (TGF-β) cytokines. In early-stage breast cancers, TGF-β exhibits tumor suppressor activity by repressing cell proliferation and inducing cell death, whereas in advanced-stage tumors, TGF-β promotes invasion and metastatic dissemination. The molecular mechanisms underlying pro-oncogenic activities of TGF-β are not fully understood. The present study validates the role of TGF-β signaling in cancer progression and explores mediators of pro-oncogenic TGF-β activities using the LM3 mammary adenocarcinoma cell line, derived from a spontaneous murine mammary adenocarcinoma. Expression of kinase-inactive TGF-β receptors decreased both basal and TGF-β-induced invasion. Analysis of signal transduction mediators showed that p38MAPK and MEK contribute to TGF-β stimulation of cell motility and invasion. TGF-β disrupted the epithelial actin structures supporting cell-cell adhesions, and increased linear actin filaments. Moreover, MEK and p38MAPK pathways showed opposite effects on actin remodeling in response to TGF-β. Blockade of Raf-MEK signaling enhanced TGF-β induction of actin stress-fibers whereas p38MAPK inhibitors blocked this effect. A novel observation was made that TGF-β rapidly activates the actin nucleation Arp2/3 complex. In addition, TGF-β stimulated matrix metalloproteinase MMP-9 secretion via a MAPK-independent pathway. Experiments using syngeneic mice showed that kinase-inactive TGF-β receptors inhibit the first stages of LM3 tumor growth in vivo. Our studies demonstrate that autocrine TGF-β signaling contributes to the invasive behavior of mammary carcinoma cells. Moreover, we show that both MAPK-dependent and -independent pathways are necessary for TGF-β-induced effects. Therefore, MEK-ERK and p38 MAPK pathways are potential venues for therapeutic intervention in pro-oncogenic TGF-β signaling.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2035834, encodeId=22db2035834e8, content=<a href='/topic/show?id=575c1e341a8' target=_blank style='color:#2F92EE;'>#TGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17341, encryptionId=575c1e341a8, topicName=TGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56ea361, createdName=changhe713, createdTime=Fri Jan 04 03:09:00 CST 2013, time=2013-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864357, encodeId=434e186435e2e, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Feb 05 17:09:00 CST 2013, time=2013-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717882, encodeId=e2de1e1788229, content=<a href='/topic/show?id=c95711284ca' target=_blank style='color:#2F92EE;'>#MAPK#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11284, encryptionId=c95711284ca, topicName=MAPK)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21d332479882, createdName=lidong51, createdTime=Fri Jul 13 15:09:00 CST 2012, time=2012-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441346, encodeId=f00614413468d, content=<a href='/topic/show?id=58dd1e34591' target=_blank style='color:#2F92EE;'>#TGF-β#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17345, encryptionId=58dd1e34591, topicName=TGF-β)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=496f4824495, createdName=ms6980045490879608, createdTime=Wed Jul 04 09:09:00 CST 2012, time=2012-07-04, status=1, ipAttribution=)]
    2013-01-04 changhe713
  2. [GetPortalCommentsPageByObjectIdResponse(id=2035834, encodeId=22db2035834e8, content=<a href='/topic/show?id=575c1e341a8' target=_blank style='color:#2F92EE;'>#TGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17341, encryptionId=575c1e341a8, topicName=TGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56ea361, createdName=changhe713, createdTime=Fri Jan 04 03:09:00 CST 2013, time=2013-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864357, encodeId=434e186435e2e, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Feb 05 17:09:00 CST 2013, time=2013-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717882, encodeId=e2de1e1788229, content=<a href='/topic/show?id=c95711284ca' target=_blank style='color:#2F92EE;'>#MAPK#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11284, encryptionId=c95711284ca, topicName=MAPK)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21d332479882, createdName=lidong51, createdTime=Fri Jul 13 15:09:00 CST 2012, time=2012-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441346, encodeId=f00614413468d, content=<a href='/topic/show?id=58dd1e34591' target=_blank style='color:#2F92EE;'>#TGF-β#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17345, encryptionId=58dd1e34591, topicName=TGF-β)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=496f4824495, createdName=ms6980045490879608, createdTime=Wed Jul 04 09:09:00 CST 2012, time=2012-07-04, status=1, ipAttribution=)]
    2013-02-05 minlingfeng
  3. [GetPortalCommentsPageByObjectIdResponse(id=2035834, encodeId=22db2035834e8, content=<a href='/topic/show?id=575c1e341a8' target=_blank style='color:#2F92EE;'>#TGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17341, encryptionId=575c1e341a8, topicName=TGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56ea361, createdName=changhe713, createdTime=Fri Jan 04 03:09:00 CST 2013, time=2013-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864357, encodeId=434e186435e2e, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Feb 05 17:09:00 CST 2013, time=2013-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717882, encodeId=e2de1e1788229, content=<a href='/topic/show?id=c95711284ca' target=_blank style='color:#2F92EE;'>#MAPK#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11284, encryptionId=c95711284ca, topicName=MAPK)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21d332479882, createdName=lidong51, createdTime=Fri Jul 13 15:09:00 CST 2012, time=2012-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441346, encodeId=f00614413468d, content=<a href='/topic/show?id=58dd1e34591' target=_blank style='color:#2F92EE;'>#TGF-β#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17345, encryptionId=58dd1e34591, topicName=TGF-β)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=496f4824495, createdName=ms6980045490879608, createdTime=Wed Jul 04 09:09:00 CST 2012, time=2012-07-04, status=1, ipAttribution=)]
    2012-07-13 lidong51
  4. [GetPortalCommentsPageByObjectIdResponse(id=2035834, encodeId=22db2035834e8, content=<a href='/topic/show?id=575c1e341a8' target=_blank style='color:#2F92EE;'>#TGF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17341, encryptionId=575c1e341a8, topicName=TGF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56ea361, createdName=changhe713, createdTime=Fri Jan 04 03:09:00 CST 2013, time=2013-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864357, encodeId=434e186435e2e, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Tue Feb 05 17:09:00 CST 2013, time=2013-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1717882, encodeId=e2de1e1788229, content=<a href='/topic/show?id=c95711284ca' target=_blank style='color:#2F92EE;'>#MAPK#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11284, encryptionId=c95711284ca, topicName=MAPK)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21d332479882, createdName=lidong51, createdTime=Fri Jul 13 15:09:00 CST 2012, time=2012-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441346, encodeId=f00614413468d, content=<a href='/topic/show?id=58dd1e34591' target=_blank style='color:#2F92EE;'>#TGF-β#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17345, encryptionId=58dd1e34591, topicName=TGF-β)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=496f4824495, createdName=ms6980045490879608, createdTime=Wed Jul 04 09:09:00 CST 2012, time=2012-07-04, status=1, ipAttribution=)]

相关资讯

Int J Oncol:阻断缺氧调控的TMPRSS4治疗肿瘤

早期研究证实TMPRSS4的过度表达与胰腺癌、大肠癌和甲状腺癌等类型癌症的发生发展有关。TMPRSS4是一种细胞表面跨膜丝氨酸蛋白酶,这一蛋白的表达对肿瘤细胞的迁移和转移有作用。 过去,有几项研究探讨了TMPRSS4基因表达水平以及蛋白产物。最近刊登在Int J Oncol杂志上的一则研究中,研究人员用定量RT-PCR和蛋白质染色来评估原发性非小细胞肺癌(NSCLC)组织和肺肿瘤细胞株中TMPR

Lancet Oncol:脑瘤治疗的新遗传标记物

近日,英国诺丁汉大学研究人员发现脑癌3套遗传标记物,可能为致命的脑瘤诊断带来新的希望。 这项最新研究由Richard Grundy教授率领,发表在权威杂志Lancet Oncology最新一期上。 尽管需要新的、更有效的治疗手段,早些年也已经开展了一系列研究,但取得的成绩并不如人意。这项诺丁汉大学完成的研究旨在筛选出可用来提高癌症治疗功效和开展治疗的分子标记物。 诺丁汉大学与加拿大多伦多病童

Lancet Oncol:发现脑肿瘤的新遗传标记

       来自英国诺丁汉大学的研究人员找到了一种致死性儿童脑肿瘤的的遗传标记,有可能为开发出新诊断工具平铺道路。        这一研究成果发表在最新出版的《柳叶刀肿瘤学》(Lancet Oncology)杂志上,由诺丁汉大学儿童脑肿瘤研究中心的Richard Grundy教授和博士后研究人员Suzanne

Int J Oncol:川芎嗪靶向COX-2抑制肿瘤转移

环氧化酶(cyclooxygenase,COX)是参与花生四烯酸的环氧酶代谢途径中的限速酶,可催化花生四烯酸转化为前列腺素(prostaglandins,PGs)。近年来研究显示,COX-2在一些肿瘤中存在过度表达现象,提示COX-2可能与肿瘤的发生发展密切相关。 环氧合酶(COX)-2在肺癌中起着重要作用,是肺癌侵袭和转移的关键因素。传统中药川芎有效成分川芎嗪(TMP),历来用于治疗神经、血管